HC Wainwright reaffirmed their buy rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note issued to investors on Friday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.
Other analysts also recently issued research reports about the stock. StockNews.com upgraded shares of Prime Medicine to a “sell” rating in a report on Wednesday, August 7th. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price objective on shares of Prime Medicine in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $13.50.
Read Our Latest Stock Analysis on Prime Medicine
Prime Medicine Trading Down 4.0 %
Prime Medicine (NYSE:PRME – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.06). Research analysts predict that Prime Medicine will post -1.75 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. ORG Partners LLC purchased a new stake in shares of Prime Medicine in the second quarter valued at about $29,000. National Bank of Canada FI purchased a new position in Prime Medicine in the second quarter worth $34,000. Nisa Investment Advisors LLC raised its holdings in Prime Medicine by 22,652.9% during the second quarter. Nisa Investment Advisors LLC now owns 7,736 shares of the company’s stock worth $40,000 after purchasing an additional 7,702 shares during the last quarter. ProShare Advisors LLC boosted its position in Prime Medicine by 19.8% during the first quarter. ProShare Advisors LLC now owns 15,276 shares of the company’s stock worth $107,000 after purchasing an additional 2,520 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in Prime Medicine during the second quarter worth $97,000. Institutional investors and hedge funds own 70.37% of the company’s stock.
Prime Medicine Company Profile
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Read More
- Five stocks we like better than Prime Medicine
- What is the Euro STOXX 50 Index?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is MarketRankā¢? How to Use it
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Transportation Stocks Investing
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.